The head of the Russian Cabinet of Ministers Mikhail Mishustin chaired a meeting of the Presidium of the Coordination Council under the Government of the Russian Federation to combat the spread of the new coronavirus infection in Russia.

During the discussion, the head of government noted that in many regions the situation with the spread of COVID-19 "remains quite tense."

According to Mishustin, in hospitals and polyclinics, almost all forces "are aimed at combating COVID-19, and the costs for these purposes are also increasing." 

"The leaders of the regions, where the incidence rate and the health care system are seriously loaded, should more decisively apply restrictive measures," said Mishustin, noting that this applies to those municipalities where the situation is "most acute."

The head of the Ministry of Health Mikhail Murashko spoke in more detail about the situation.

According to him, today in 17 regions of Russia there is a situation in which less than 5% of the bed capacity is free.

“The Kaliningrad region and St. Petersburg are of the greatest concern to us,” the minister said.

The head of Rospotrebnadzor Anna Popova, in turn, spoke about the average daily incidence of COVID-19.

According to her, this indicator differs greatly in different regions of the country: “If in the Russian Federation as a whole it was 17.8 per 100 thousand of the population over the past week, in the Republic of Tatarstan - 2.1, then in the Republic of Karelia it is 63 per 100 thousand population ".

“That is, the epidemiological situation correlates with the measures taken, with the exactingness of their application and looks very different in all 85 regions,” the head of Rospotrebnadzor noted.

She added that since mid-October there has been a decrease in the reproductive rate to one, but so far unstable: "In recent days it is 1.2, but in most regions - 62 subjects - this indicator is less than or equal to one."

At the same time, Popova noted the overall positive dynamics.

“In Russia as a whole, we see a slowdown in growth rates, however, the average daily incidence rate is very different in different regions of Russia,” she concluded.

Latest incidence data

Over the past day, 26,402 new cases of coronavirus were detected in 85 regions of Russia.

Since the beginning of the pandemic, 2,322,056 cases of coronavirus infection have been identified in Russia, 1,803,467 people have recovered, including 24,763 in the last 24 hours.

At the same time, 40,464 people have died from complications that developed against the background of coronavirus infection and concomitant diseases.

During the day, the number of deaths increased by 569.

The regions with the lowest growth rate of COVID-19 were the Altai Republic, the Nenets Autonomous Okrug (both 0.5% each), the Khanty-Mansi Autonomous Okrug, the Republic of Dagestan (both 0.6%).

The largest number of new cases of coronavirus over the past day was detected in Moscow (6524), St. Petersburg (3697), Moscow (1104), Nizhny Novgorod (462) regions, the Republic of Karelia (427).

Also, Russian Deputy Prime Minister Dmitry Chernyshenko said that all regions of the country were provided with technical access to a single telephone number for coronavirus - 122 - for the convenience of dialing citizens to medical institutions. 

  • Temporary hospital for patients with COVID-19, deployed at the Krylatskoye ice palace

  • RIA News

  • © Ilya Pitalev

According to the latest data from the American Johns Hopkins University, over 63.35 million cases of coronavirus infection have been identified in the world.

The largest number of cases is in the United States (more than 13.5 million), India (9.5 million), Brazil (6.3 million).

At the same time, more than 1.4 million people worldwide died from complications associated with coronavirus infection and other diseases, including 268 thousand in the United States, 173 thousand in Brazil and 138 thousand in India.

“Last week was the first drop in the number of new cases in the world since the beginning of September due to a decrease in the number of cases in Europe, which was due to the effective but heavy measures that have been implemented.

This is good news, but we must interpret it with great care, ”said Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO) at a briefing.

He also urged not to politicize research to identify the source of COVID-19.

According to him, experts from different countries will base their opinions on scientific data.

“Our position was extremely clear and tough.

We are working to identify the source of the virus, because this will help the world understand its genesis and prevent future outbreaks, ”said the WHO Director General.

Vaccine situation

Meanwhile, a number of countries reported that they are considering the possibility of using the Russian Sputnik V vaccine, developed by specialists from the Center.

Gamalei.

This was stated by the Ambassador of Oman to Moscow Youssef Issa Ali Al Zajali, Prime Minister of Serbia Ana Brnabic and Ambassador of Palestine to the Russian Federation Abdelhafiz Nofal

At the same time, Serbia is ready to study the possibility of joint production of the drug.

In addition, Russian President Vladimir Putin in a telephone conversation discussed with the President of Uzbekistan Shavkat Mirziyoyev the fight against coronavirus, including the use of the Russian vaccine.

The world's first vaccine against coronavirus infection COVID-19, dubbed Sputnik V, was registered in Russia on August 11.

It was developed by the National Research Center for Epidemiology and Microbiology named after Honorary Academician N.F.

Gamalei.

On November 24, the Russian Direct Investment Fund reported that the effectiveness of the Sputnik V vaccine on the 42nd day after the first injection (21st day after the second) exceeds 95%, while on the 28th day the effectiveness of the drug was 91.4% ...

At the same time, the RDIF indicated that the drug will be sold on the international market at a price of less than $ 10 per dose.

At the same time, the American company Moderna has asked the Food and Drug Administration (FDA) for an emergency use of the developed coronavirus vaccine.

In the initial analysis, the drug showed an efficiency of 94.1% in the third phase of testing.